Precigen (PGEN)
Commercializes PAPZIMEOS while developing selected gene and cell therapies.
$7.49
vs last close−0.40 (−5.07%)
Something off on this page? Send us feedback.
Next report
Nov 12, 26
in 50 days
EPS estimate
$0.09
Revenue estimate
$69.2M
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported−$0.04−$0.18−$0.11−$1.06−$0.07−$0.02$0.05Pending
Estimate−$0.06−$0.08−$0.09−$0.08−$0.10−$0.03−$0.01$0.09
Surprise+33.3%−125.0%−26.9%−1,225.0%+33.6%+33.3%+514.3%—
RevenueReportedEstimate
Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported$1.2M$1.3M$878.0K$2.9M$4.6M$23.3M$55.0MPending
Estimate$3.0M$650.0K$952.0K$500.0K$8.4M$20.8M$28.0M$69.2M
Surprise−60.7%+106.3%−7.8%+484.4%−45.6%+11.8%+96.5%—
HistoryUpcoming
| Date / Period | Estimate | Reported | Surprise |
|---|---|---|---|
| Dec 2027 | $0.27 | — | — |
| Sep 2027 | $0.24 | — | — |
| Jun 2027 | $0.21 | — | — |
| Mar 2027 | $0.17 | — | — |
| Dec 2026 | $0.06 | — | — |
| Nov 2026 | $0.09 | — | — |
| Aug 2026 | −$0.01 | $0.05 | +514.3% |
| May 2026 | −$0.03 | −$0.02 | +33.3% |
| Mar 2026 | −$0.10 | −$0.07 | +33.6% |
| Nov 2025 | −$0.08 | −$1.06 | −1,225.0% |
| Aug 2025 | |||
| May 2025 | |||
| Mar 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Mar 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Mar 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Mar 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Mar 2021 | |||
| Nov 2020 | |||
| Aug 2020 | |||
| May 2020 | |||
| Mar 2020 | |||
| Nov 2019 | |||
| Aug 2019 | |||
| May 2019 | |||
| Feb 2019 | |||
| Nov 2018 | |||
| Aug 2018 | |||
| May 2018 | |||
| Mar 2018 | |||
| Nov 2017 | |||
| Aug 2017 | |||
| May 2017 | |||
| Mar 2017 | |||
| Nov 2016 | |||
| Aug 2016 | |||
| May 2016 | |||
| Feb 2016 | |||
| Nov 2015 | |||
| Aug 2015 |
| Date / Period | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Dec 2027 | $0.27 | — | — | $105.1M | — | — | — |
| Sep 2027 | $0.24 | — | — | $95.1M | — | — | — |
| Jun 2027 | $0.21 | — | — | $84.9M | — | — | — |
| Mar 2027 | $0.17 | — | — | $77.2M | — | — | — |
| Dec 2026 | $0.06 | — | — | $85.5M | — | — | — |
| Nov 12, 2026 | $0.09 | — | — | $69.2M | — | — | — |
| Aug 4, 2026 | −$0.01 | $0.05 | +514.3% | $28.0M | $55.0M | +96.5% | +5.5% |
| May 13, 2026 | −$0.03 | −$0.02 | +33.3% | $20.8M | $23.3M | +11.8% | +10.8% |
| Mar 25, 2026 | −$0.10 | −$0.07 | +33.6% | $8.4M | $4.6M | −45.6% | +25.5% |
| Nov 13, 2025 | −$0.08 | −$1.06 | −1,225.0% | $500.0K | $2.9M | +484.4% | +25.7% |
| Aug 12, 2025 | |||||||
| May 14, 2025 | |||||||
| Mar 19, 2025 | |||||||
| Nov 14, 2024 | |||||||
| Aug 14, 2024 | |||||||
| May 14, 2024 | |||||||
| Mar 19, 2024 | |||||||
| Nov 9, 2023 | |||||||
| Aug 9, 2023 | |||||||
| May 10, 2023 | |||||||
| Mar 6, 2023 | |||||||
| Nov 9, 2022 | |||||||
| Aug 8, 2022 | |||||||
| May 9, 2022 | |||||||
| Mar 1, 2022 | |||||||
| Nov 8, 2021 | |||||||
| Aug 9, 2021 | |||||||
| May 10, 2021 | |||||||
| Mar 1, 2021 | |||||||
| Nov 9, 2020 | |||||||
| Aug 10, 2020 | |||||||
| May 6, 2020 | |||||||
| Mar 2, 2020 | |||||||
| Nov 12, 2019 | |||||||
| Aug 8, 2019 | |||||||
| May 9, 2019 | |||||||
| Feb 28, 2019 | |||||||
| Nov 8, 2018 | |||||||
| Aug 13, 2018 | |||||||
| May 10, 2018 | |||||||
| Mar 1, 2018 | |||||||
| Nov 9, 2017 | |||||||
| Aug 9, 2017 | |||||||
| May 10, 2017 | |||||||
| Mar 1, 2017 | |||||||
| Nov 9, 2016 | |||||||
| Aug 9, 2016 | |||||||
| May 10, 2016 | |||||||
| Feb 29, 2016 | |||||||
| Nov 9, 2015 | |||||||
| Aug 10, 2015 |